Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Anna J Podolanczuk; Kerri I Aronson

doi:10.1183/13993003.00067-2024

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Eur Respir J. 2024 Feb 1;63(2):2400067. doi: 10.1183/13993003.00067-2024. Print 2024 Feb.

Authors

Anna J Podolanczuk¹, Kerri I Aronson²

Affiliations

¹ Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA ajp9012@med.cornell.edu.
² Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.

Abstract

Treatment with nintedanib slows the worsening of dyspnoea and fatigue, stabilises the degree of impact of pulmonary fibrosis, and may actually improve cough https://bit.ly/3S01WbX

Publication types

Editorial
Comment

MeSH terms

Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Indoles / pharmacology
Indoles / therapeutic use
Lung* / drug effects

Substances

nintedanib
Indoles

Abstract

Publication types

MeSH terms

Substances

Grants and funding